Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors

ABSTRACT

The invention discloses hydroxamide acids of the formula:                    
     which are useful in treating disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn&#39;s disease and degenerative cartilage loss.

This application claims to benefit of U.S. Provisional Application No.60/155,250 filed Jan. 27, 1999 now abandoned.

FIELD OF INVENTION

This invention relates to acetylenic aryl sulfonamide and phosphinicacid amide hydroxamic acids which act as inhibitors of TNF-α convertingenzyme (TACE). The compounds of the present invention are useful indisease conditions mediated by TNF-α, such as rheumatoid arthritis,osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis,Crohn's disease and degenerative cartilage loss.

BACKGROUND OF THE INVENTION

TNF-α converting enzyme (TACE) catalyzes the formation of TNF-α frommembrane bound TNF-α precursor protein. TNF-α is a pro-inflammatorycytokine that is believed to have a role in rheumatoid arthritis [Shire,M. G.; Muller, G. W. Exp. Opin. Ther. Patents 1998, 8(5), 531; Grossman,J. M.; Brahn, E. J. Women's Health 1997, 6(6), 627; Isomaki, P.;Punnonen, J. Ann. Med 1997, 29, 499; Camussi, G.; Lupia, E. Drugs, 1998,55(5), 613.] septic shock [Mathison, et. al. J. Clin. Invest. 1988, 81,1925; Miethke, et. al. J. Exp. Med. 1992, 175, 91.], graft rejection[Piguet, P. F.; Grau, G. E.; et. al J. Exp. Med. 1987, 166, 1280.],cachexia [Beutler, B.; Cerami, A. Ann. Rev. Biochem. 1988, 57, 505.],anorexia, inflammation [Ksontini, R,; MacKay, S. L. D.; Moldawer, L. L.Arch. Surg. 1998, 133, 558.], congestive heart failure [Packer, M.Circulation, 1995, 92(6), 1379; Ferrari, R.; Bachetti, T.; et. al.Circulation, 1995, 92(6), 1479.], post-ischaemic reperfusion injury,inflammatory disease of the central nervous system, inflammatory boweldisease, insulin resistance [Hotamisligil, G. S.; Shargill, N. S.;Spiegelman, B. M.; et. al. Science, 1993, 259, 87.] and HIV infection[Peterson, P. K.; Gekker, G.; et. al. J. Clin. Invest. 1992, 89, 574;Pallares-Trujillo, J.; Lopez-Soriano, F. J. Argiles, J. M. Med. Res.Reviews, 1995, 15(6), 533.]], in addition to its well-documentedantitumor properties [Old, L. Science, 1985, 230, 630.]. For example,research with anti-TNF-α antibodies and transgenic animals hasdemonstrated that blocking the formation of TNF-α inhibits theprogression of arthritis [Rankin, E. C.; Choy, E. H.; Kassimos, D.;Kingsley, G. H.; Sopwith, A. M.; Isenberg, D. A.; Panayi, G. S. Br. J.Rheumatol. 1995, 34, 334; Pharmaprojects, 1996, Therapeutic Updates 17(October), au197-M2Z.]. This observation has recently been extended tohumans as well as described in “TNF-α in Human Diseases”, CurrentPharmaceutical Design, 1996, 2, 662.

It is expected that small molecule inhibitors of TACE would have thepotential for treating a variety of disease states. Although a varietyof TACE inhibitors are known, many of these molecules are peptidic andpeptide-like which suffer from bioavailability and pharmacokineticproblems. In addition, many of these molecules are non-selective, beingpotent inhibitors of matrix metalloproteinases and, in particular,MMP-1. Inhibition of MMP-1 (collagenase 1) has been postulated to causejoint pain in clinical trials of MMP inhibitors [Scrip, 1998, 2349, 20].Long acting, selective, orally bioavailable non-peptide inhibitors ofTACE would thus be highly desirable for the treatment of the diseasestates discussed above.

Examples of sulfonamide hydroxamic acid MMP/TACE inhibitors in which a 2carbon chain separates the hydroxamic acid and the sulfonamide nitrogen,as shown below, are disclosed in WIPO international publicationsWO9816503, WO9816506, WO9816514 and WO9816520 and U.S. Pat. No.5,776,961.

U.S. Pat. Nos. 5,455,258, 5,506,242, 5,552,419, 5,770,624, 5,804,593 and5,817,822 as well as European patent application EP606,046A1 and WIPOinternational publications WO9600214 and WO9722587 disclose non-peptideinhibitors of matrix metalloproteinases and/or TACE of which the arylsulfonamide hydroxamic acid shown below, in which 1 carbon separates thehydroxamic acid and the sulfonamide nitrogen, is representative.Additional publications disclosing sulfonamide based MMP inhibitorswhich are variants of the sulfonamide-hydroxamate shown below, or theanalogous sulfonamide-carboxylates, are European patent applicationsEP-757037-A1 and EP-757984-A1 and WIPO international publicationsWO9535275, WO9535276, WO9627583, WO9719068, WO9727174, WO9745402,WO9807697, and WO9831664, WO9833768, WO9839313, WO9839329, WO9842659 andWO9843963. The discovery of this type of MMP inhibitor is furtherdetailed by MacPherson, et. al. in J. Med. Chem., (1997), 40, 2525 andTamura, et. al. in J. Med. Chem (1998), 41, 640.

Publications disclosing β-sulfonamide-hydroxamate inhibitors of MMPsand/or TACE in which the carbon alpha to the hydroxamic acid has beenjoined in a ring to the sulfonamide nitrogen, as shown below, includeU.S. Pat. No. 5,753,653, WIPO international publications WO9633172,WO9720824, WO9827069, WO9808815, WO9808822, WO9808823, WO9808825,WO9834918, WO9808827, Levin, et. al. Bioorg. & Med. Chem. Letters 1998,8, 2657 and Pikul, et. al. J. Med. Chem. 1998, 41, 3568.

The patent applications DE19,542,189-A1, WO9718194, and EP803505disclose additional examples of cylic sulfonamides as MMP and/or TACEinhibitors. In this case the sulfonamide-containing ring is fused to aaromatic or heteroaromatic ring.

Analogous to the sulfonamides are the phosphinic acid amide hydroxamicacid MMP/TACE inhibitors, exemplified by the structure below, which havebeen disclosed in WIPO international publication WO9808853.

Sulfonamide MMP/TACE inhibitors in which a thiol is the zinc chelatinggroup, as shown below, have been disclosed in WIPO internationalapplication 9803166.

It is an object of this invention to provide aryl sulfonamide andphosphinic acid amide hydroxamic acid MMP/TACE inhibitors in which the Y(the sulfonyl or phosphinyl aryl) is para-substituted with a substitutedbutynyl moiety or a propargylic ether, amine or sulfide. These compoundsprovide enhanced levels of inhibition of the activity of TACE in vitroand in a cellular assay and/or selectivty over MMP-1. These compoundsmay therefore be used in the treatment of diseases mediated by TNF.

SUMMARY OF THE INVENTION

The TACE and MMP inhibiting ortho-sulfonamido hydroxamic acids of thepresent invention are represented by the formula:

where the C(═O)NHOH moiety and the —NR5- moiety are bonded to adjacentcarbons;

wherein

X is SO₂ or —P(O)R₁₀;

Y is 5-10 membered heteroaryl ring having from 1-3 heteroatoms selectedfrom N, NR9, S and O, phenyl or naphthyl; with the proviso that X and Zmay not be bonded to adjacent atoms of Y:

Z is O, NH, CH₂, or S;

R₅ is hydrogen or alkyl of 1-6 carbon atoms;

R₆ and R₇ are each, independently, hydrogen or methyl;

R₈ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms,alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, a 5-7membered heteroaryl having 1-3 heteroatoms selected from N, NR9, S andO, a 5-7 membered heterocycloalkyl having 1 or 2 heteroatoms selectedfrom N, NR9, S and O, or phenyl;

R₉ is hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbonatoms, or phenyl;

R₁₀ is alkyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms,phenyl, or 5-7 membered heteroaryl, having 1-3 heteroatoms selected fromN, NR9, S and O;

R11 and R12 are, independently, hydrogen, alkyl of 1-6 carbon atoms,cycloalkyl of 3-6 carbon atoms, a 5-7 membered heteroaryl having 1-3heteroatoms selected from N, NR9, S and O, a 5-7 memberedheterocycloalkyl having 1 or 2 heteroatoms selected from N, NR9, S andO, or phenyl, and the optional double bond represented by the dottedline is present; or

R11 and R12, together with the carbons to which they are attached, forma 5-10 membered saturated or unsaturated mono or bicyclic alkyl ringoptionally fused to one of a 5 to 7 membered saturated or unsaturatedcycloalkyl ring, a 5-7 membered heteroaryl having 1-3 heteroatomsselected from N, NR9, S and O, a 5-7 membered heterocycloalkyl having 1or 2 heteroatoms selected from N, NR9, S and O, phenyl or napthyl rings;or

R11 and R12, together with the carbons to which they are attached form a5-10 membered saturated or unsaturated mono- or bicyclicheterocycloalkyl having 1-2 heteroatoms selected from N, NR9, S and O,optionally fused to one of a 5-7 membered mono or bi-cyclic heteroarylhaving 1-3 heteroatoms selected from N, NR9, S and O, a 5-7 memberedsaturated or unsaturated cycloalkyl ring or a phenyl or napthyl ring;

the dotted line represents an optional double bond;

and n=0-2; or a pharmaceutically acceptable salt thereof.

Preferred compounds of this invention include compounds of structure Bwherein X is SO₂.

More preferred compounds of this invention include compounds ofstructure B wherein X is SO₂ and Y is a phenyl ring substituted at the1- and 4-positions by X and Z, respectively.

More preferred compounds of this invention include compounds ofstructure B wherein X is SO₂, Y is a phenyl ring substituted at the 1-and 4-positions by X and Z, respectively, and Z is oxygen.

More preferred compounds of this invention include compounds ofstructure B wherein X is SO₂, Y is a phenyl ring substituted at the 1-and 4-positions by X and Z, respectively, Z is oxygen and R₆ and R₇ arehydrogen.

More preferred compounds of this invention include compounds ofstructure B wherein X is SO₂, Y is a phenyl ring substituted at the 1-and 4-positions by X and Z, respectively, Z is oxygen, R₆ and R₇ arehydrogen and R₈ is —CH₂OH or methyl.

Still more preferred compounds of the present invention are

(1R,2R)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}(methyl)amino]-N-hydroxycyclohexanecarboxamide;

(1R,2R)-2-({[4-(2-Butynyloxy)phenyl]sulfonyl}amino)-N-hydroxycyclohexanecarboxamide;

3-({[4-(2-Butynyloxy)phenyl]sulfonyl}amino)-N-hydroxypropanamide;

3-({[4-(2-Butynyloxy)phenyl]sulfonyl}(methyl)amino)-N-hydroxypropanamide;

(1R,2S)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}amino)-N-hydroxycyclohexanecarboxamide;

(1R,2S)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}(methyl)amino]N-hydroxycyclopentanecarboxamide;

(Cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N-hydroxycyclohexanecarboxamide;

(Cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]-N-hydroxycyclohexanecarboxamide;

(1R, 2R, 3S,4R)-(Cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N-hydroxybicyclo[2.2.1]heptane-2-carboxamide; and

(1R, 2R, 3S, 4R)-(Cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)-N-hydroxybicyclo [2.2.1]heptane-2-carboxamide.

Heteroaryl, as used throughout, is a 5-10 membered mono- or bicyclicring having from 1-3 heteroatoms selected from N, NR9, S and O.Heteroaryl is preferably

wherein K is NR9, O or S and R9 is hydrogen, alkyl of 1-6 carbon atoms,cycloalkyl of 3-6 carbon atoms, or phenyl. Preferred heteroaryl ringsinclude pyrrole, furan, thiophene, pyridine, pyrimidine, pyridazine,pyrazine, triazole, pyrazole, imidazole, isothiazole, thiazole,isoxazole, oxazole, indole, isoindole, benzofuran, benzothiophene,quinoline, isoquinoline, quinoxaline, quinazoline, benzotriazole,indazole, benzimidazole, benzothiazole, benzisoxazole, and benzoxazole.

Heteroaryl groups of the present invention may optionally be mono- ordi-substituted.

Heterocycloalkyl as used herein refers to a 5 to 10 membered saturatedor unsaturated mono or bi-cyclic ring having 1 or 2 heteroatoms selectedfrom N, NR4, S or O. Heterocycloalkyl rings of the present invention arepreferably selected from

wherein M is NR4, O or S and R4 is hydrogen, alkyl of 1-6 carbon atoms,cycloalkyl of 3-6 carbon atoms, phenyl, naphthyl, L, —S(O)_(n)R₂,—COOR₂, —CONR₂R₃, —SO₂NR₂R₃ or —COR₂. Preferred heterocycloalkyl ringsinclude piperidine, piperazine, morpholine, tetrahydropyran,tetrahydrofuran or pyrrolidine. Heterocycloalkyl groups of the presentinvention may optionally be mono- or di-substituted.

Aryl, as used herein refers to phenyl or naphthyl which may, optionallybe mono-, di- or tri-substituted.

Alkyl, alkenyl, alkynyl, and perfluoroalkyl include both straight chainas well as branched moieties. Alkyl, alkenyl, alkynyl, and cycloalkylgroups may be unsubstituted unsubstituted (carbons bonded to hydrogen,or other carbons in the chain or ring) or may be mono- orpoly-substituted. Cycloalkyl groups may be mono or bicyclic. Examples ofmonocyclic cycloalkyl groups include cyclopentyl and cyclohexyl.Examples of bicyclic cycloalkyl groups include bicycloheptane andadamantyl.

Halogen means bromine, chlorine, fluorine, and iodine.

Suitable substituents of aryl, heteroaryl, alkyl, alkenyl, alkynyl, andcycloalkyl include, but are not limited to halogen, alky of 1-6 carbonatoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms,cyclocalkyl of 3-6 carbon atoms, —OR₂, —CN, —COR₂, perfluoroalkyl of 1-4carbon atoms, —O-perfluoroalkyl of 1-4 carbon atoms, —CONR₂R₃,—S(O)_(n)R₂ —OPO(OR₂)OR₃, —PO(OR₂)R₃, —OC(O)NR₂R₃, —C(O)NR₂OR₃, —COOR₂,—SO₃H, —NR₂R₃, —N[(CH₂)₂]₂NR₂, —NR₂COR₃, —NR₂COOR₃, —SO₂NR₂R₃, —NO₂,—N(R₂)SO₂R₃, —NR₂CONR₂R₃, —NR₂C(═NR₃)NR₂R₃,—NR₂C(═NR₃)N(SO₂)R₂R₃,NR₂C(═NR₃)N(C═O)R₂R₃, —SO₂NHCOR₄, —CONHSO₂R₄, -tetrazol-5-yl, —SO₂NHCN,—SO₂NHCONR₂R₃, phenyl, naphthyl, heteroaryl or heterocycloalkyl;

wherein

—NR₂R₃ may form a pyrrolidine, piperidine, morpholine, thiomorpholine,oxazolidine, thiazolidine, pyrazolidine, piperazine, or azetidine ring;

R₂ and R₃ are each, independently, hydrogen, alkyl of 1-6 carbon atoms,cycloalkyl of 3-6 carbon atoms, phenyl, naphthyl, heteroaryl orheterocycloalkyl;

R₄ is hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbonatoms, phenyl, naphthyl, L, —S(O)_(n)R₂, —COOR₂, —CONR₂R₃, —SO₂NR₂R₃ or—COR₂; L is heteroaryl and n is 0-2.

Suitable substituents of heterocycloalkyl groups of the presentinvention include, but are not limited to alkyl of 1-6 carbon atoms,cycloalkyl of 3-6 carbon atoms, phenyl, naphthyl, heteroaryl andheterocycloalkyl.

When a moiety contains more than substituent with the same designationeach of those substituents may be the same or different.

Pharmaceutically acceptable salts can be formed from organic andinorganic acids, for example, acetic, propionic, lactic, citric,tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic,hydrochloric, hydrobromic, phosphoric, nitric, sulfuric,methanesulfonic, naphthalenesulfonic, benzenesulfonic, toluenesulfonic,camphorsulfonic, and similarly known acceptable acids when a compound ofthis invention contains a basic moiety. Salts may also be formed fromorganic and inorganic bases, preferably alkali metal salts, for example,sodium, lithium, or potassium, when a compound of this inventioncontains an acidic moiety.

The compounds of this invention may contain an asymmetric carbon atomand some of the compounds of this invention may contain one or moreasymmetric centers and may thus give rise to optical isomers anddiastereomers. While shown without respect to stereochemistry, thepresent invention includes such optical isomers and diastereomers; aswell as the racemic and resolved, enantiomerically pure R and Sstereoisomers; as well as other mixtures of the R and S stereoisomersand pharmaceutically acceptable salts thereof. It is recognized that oneoptical isomer, including diastereomer and enantiomer, or stereoisomermay have favorable properties over the other. Thus when disclosing andclaiming the invention, when one racemic mixture is disclosed, it isclearly contemplated that both optical isomers, including diastereomersand enantiomers, or stereoisomers substantially free of the other aredisclosed and claimed as well.

The compounds of this invention are shown to inhibit the enzymes MMP-1,MMP-9, MMP-13 and TNF-α converting enzyme (TACE) and are thereforeuseful in the treatment of arthritis, tumor metastasis, tissueulceration, abnormal wound healing, periodontal disease, graftrejection, insulin resistance, bone disease and HIV infection. Inparticular, the compounds of the invention provide enhanced levels ofinhibition of the activity of TACE in vitro and in cellular assay and/orenhanced selectivity over MMP-1 and are thus particularly useful in thetreatment of diseases mediated by TNF.

The invention is further directed to a process for making compounds ofstructure B involving one or more reactions as follows:

1) alkylating a compound of formula I, or a salt or solvate thereof,

 into a compound of formula II

2) reacting a compound of formula II above, or a salt or solvatethereof, with a chlorinating agent such as thionyl chloride,chlorosulfonic acid, oxalyl chloride, phosphorus pentachloride, or otherhalogenating agents such as fluorosulfonic acid or thionyl bromide to acompound of formula III:

wherein J is fluorine, bromine, chlorine.

The resultant sulfonyl chloride, fluoride or bromide, may be furtherconverted into triazolide, imidazolide or benzothiazolide derivatives,where J is 1,2,4-triazolyl, imidazol-yl or benzotriazolyl, by reactingthe compound with 1,2,4-triazole, imidazole or benzotriazole,respectively. R₆, R₇ and R₈ are as defined above.

The invention is still further directed to a process for makingcompounds of structure B involving one or more reactions as follows:

1) alkylating phenol, or a salt or solvate thereof, into a compound offormula IV:

2) reacting a compound of formula IV above, or a salt or solvate thereofwith chlorosulfonic acid to prepare a compound of formula II above.

Particularly preferred intermediates are compounds of formulae II andIII, with the proviso that R6 is not hydrogen.

The invention compounds are prepared using conventional techniques knownto those skilled in the art of organic synthesis. The starting materialsused in preparing the compounds of the invention are known, made byknown methods or are commercially available.

Those skilled in the art will recognize that certain reactions are bestcarried out when other potentially reactive functionality on themolecule is masked or protected, thus avoiding undesirable sidereactions and/or increasing the yield of the reaction. To this end,those skilled in the art may use protecting groups. Examples of theseprotecting group moieties may be found in T. W. Greene, P. G. M. Wuts“Protective Groups in Organic Synthesis”, 2^(nd) Edition, 1991, Wiley &Sons, New York Reactive side chain functionalities on amino acidstarting materials are preferably protected. The need and choice ofprotecting groups for a particular reaction is known to those skilled inthe art and depends on the nature of the functional group to beprotected (hydroxy, amino, carboxy, etc.), the structure and stabilityof the molecule of which the substituent is part and the reactionconditions.

When preparing or elaborating compounds of the invention containingaryl, heteroaryl or heterocyclic rings, those skilled in the artrecognize that substituents on that ring may be prepared before, afteror concomitant with construction of the ring. For clarity, substituentson such rings have been omitted from the schemes herein below.

Those skilled in the art will recognize that the nature and order of thesynthetic steps presented may be varied for the purpose of optimizingthe formation of the compounds of the invention.

The hydroxamic acid compounds of the invention, 1, are preparedaccording to Scheme 1 by converting a carboxylic acid, 2, into thecorresponding acid chloride or anhydride, or by reacting it with asuitable peptide coupling reagent, followed by reaction withhydroxylamine to give 1, or with a protected hydroxylamine derivative togive 3. Compounds 3, wherein R₃₀ is a t-butyl, benzyl, trialkylsilyl orother suitable masking group may then be deprotected by known methods toprovide the hydroxamic acid 1. Throughout the schemes A is R₁₁ and R₁₂are hereinbefore defined.

Carboxylic acids 2 may be prepared as shown in Scheme 2. Amino acidderivative 4, in which R₄₀ is hydrogen or a suitable carboxylic acidprotecting group, may be sulfonylated or phosphorylated by reacting withcompounds 5, in which J is a suitable leaving group including, but notlimited to chlorine. The N—H compound 6 may then be alkylated with R₃Jand a base such as potassium carbonate or sodium hydride in a polaraprotic solvent such as acetone, N,N-dimethylformamide (DMF), ortetrahydrofuran (THF) to provide sulfonamide 7. Compound 7 is alsoavailable through direct reaction of 5 with an N-substituted amino acidderivative, 8. Conversion of 7 into the carboxylic acid is performed byacid, base hydrolysis, or other method consistent with the choice ofprotecting group R₄₀ and the presence of a carbon-carbon triple bond.

Methods of preparation of sulfonylating agents 5 are shown in Scheme 3.Thus, sulfonic acid salts 9, where ZR₅₀ is a hydroxy, thiol orsubstituted amino moiety may be alkylated with acetylenes 10, where J isa suitable leaving group such as halogen mesylate, tosylate, or triflateto give 11. Acetylenes 10 are commercially available or known compounds,or they may be synthesized by known methods by those skilled in the art.The sulfonic acid salts 11 may be converted into the correspondingsulfonyl chloride or other sulfonylating agent 5 by known methods, suchas reaction with oxalyl chloride or other reagent compatible withsubstituents R₆, R₇ and R₈ and the acetylene. Alternatively, thedisulfide 12 may be converted into diacetylene 13 by reaction withcompounds 10, followed by reduction of the disulfide bond to provide theanalogous thiols which may be converted into 5 by known methods.Alkylation of the phenol, thiophenol, aniline or protected aniline 14with 10 to give 15, followed by reaction with chlorosulfonic acidprovide sulfonic acids 16 which are readily converted into 5 with oxalylchloride or similar reagents. Thiophenols 17 are also precursors to 5via protection of the thiol, alkylation of ZH, where Z is O, N or S, anddeprotection of the sulfur followed by oxidation to the sulfonic acid16.

The phosphorus containing analogs of 8 may be prepared using similarmethodology, as shown in Scheme 4.

The acetylenic side chain may also be appended after sulfonylation orphosphorylation of the amino acid derivative, as shown in Scheme 5.Thus, the amino acid derivatives 4 and 8 can be sulfonylated orphosphorylated with compounds 20, where ZR₅₀ is hydroxy or protectedhydroxy, thiol or amine, and, if necessary, alkylated with R₇J as inScheme 2, to give 21. Removal of the R₅₀ masking group to give 22 andsubsequent alkylation of the resulting phenol, thiol or amine with 10provides 7. In the case where ZR₅₀ is equal to OH, no deprotection stepis required to give 22.

The propargylic amine analogs of 7 can be synthesized as shown in Scheme6 starting from the amino acid derivatives 4 and/or 8. Sulfonylation orphosphorylation with para-nitro aryl compound 23, for example4-nitrobenzenesulfonyl chloride, followed by alkylation with R₅J (for 4)using a base such as potassium carbonate or sodium hydride in DMFprovides 24. Reduction of the nitro moiety with hydrogen and palladiumon carbon, tin chloride or other known method to give aniline 25 andsubsequent alkylation with 10 then provides 7. Aniline 25 may bederivatized with a suitable nitrogen protecting group, such ast-butoxycarbonyl, to give 26 prior to alkylation with 10 subsequentdeprotection after the alkylation step.

Acetylenic derivatives 7 are also accessible via the fluoro compounds27, readily prepared from the amino acid derivatives 4 and/or 8 byreaction with fluoraryl 26, as shown in Scheme 7. Displacement of thefluorine of 27 in the presence of a base such as sodium hydride with amasked hydroxy, thiol, or amino group (HZR₇₀, where R₇₀ is a suitableprotecting group) in a polar aprotic solvent such as DMF, followed bydeprotection gives 28, which can then be alkylated with 10 to provide 7.Conversion of 27 to 28, where Z is sulfur, might also be accomplishedwith Na₂S, K₂S, NaSH or KS(C═S)OEt. The fluorine of 27 can also bedisplaced in a polar aprotic solvent with the propargylic derivative 29,where Z is O, S or NH, in the presence of a base such as sodium hydride,to give 7 directly.

Compound 7, wherein Z is a methylene group, is available via 30, asshown in Scheme 8. Benzylic bromination of 30 with N-bromosuccinimide ina chlorinated hydrocarbon solvent provides bromide 31. This is followedby displacement of the bromide with the appropriate propynyl cuprate toprovide sulfonamide 8.

Compounds of the invention can also be prepared by modifyingsubstituents on the acetylenic side chain at any stage aftersulfonylation or phosphorylation of the starting amino acid derivatives4 or 8. Functional groups such as halogen, hydroxy, amino, aldehyde,ester, ketone, etc. may be manipulated by standard methods to form themoieties defined by R₁-R₈ of compounds 1. It is recognized by thoseskilled in the, art of organic synthesis that the successful use ofthese methods is dependent upon the compatibility of substituents onother parts of the molecule. Protecting groups and/or changes in theorder of steps described herein may be required.

Some of the methods available for the derivatization of compounds ofstructure 32 (equivalent to compound 7 wherein R₁₂ is hydrogen) areshown in Scheme 9. Metallation of the terminal acetylene 32 followed byaddition of an aldehyde or alkyl halide, sulfonate or triflate providesderivatives 33 and 34. Reaction of 32 with formaldehyde and an amineprovides the Mannich addition product 35. Cyanogen bromide addition to35 gives the propargylic bromide 36 which may be displaced with avariety of nucleophiles to give, for example, ethers, thioethers andamines 37. Palladium catalyzed coupling reactions of 32 provide the arylor heteroaryl acetylenes 38. It is recognized by those skilled in theart of organic synthesis that the successful use of these methods isdependent upon the compatibility of substituents on other parts of themolecule. Protecting groups and/or changes in the order of stepsdescribed herein may be required.

The following specific examples illustrate the preparation ofrepresentative compounds of this invention. The starting materials,intermediates, and reagents are either commercially available or can bereadily prepared following standard literature procedures by one skilledin the art of organic synthesis.

EXAMPLE 1 (trans)-2-(4-Methoxybenzenesulfonyl)aminocyclohexanecarboxylicacid

To a room temperature solution of 1 g (6.8 mmol) oftrans-2-amino-1-cyclohexylcarboxylic acid in 50 ml of dioxane: H₂O (1:1)containing 1.7 ml (12.2 mmol) of triethylamine was added 1.54 g (7.46mmol) of 4-methoxybenzenesulfonyl chloride. The mixture was stirred at25° C. for 18 h. The resulting mixture was diluted with pentane toafford 1.119 g (51%) of the desired sulfonamide product as a whitesolid. ¹H NMR(DMSO-d₆): 7.7 ppm (dd, 2H, Ar), 7.4 ppm (d, 1H, NH), 7.0ppm (dd, 2H, Ar), 3.8 ppm (s, 3H, OMe), 3.5 ppm (m, 1H, N—CH), 1.0-1.7ppm (m, 9H, hydrocarbon).

EXAMPLE 2 (cis)-2-(4-Methoxybenzenesulfonyl)aminocyclohexanecarboxylicacid

In the same manner as described in Example 1, 2.5 g (17 mmol) ofcis-2-amino-1-cyclohexylcarboxylic acid provided 3.283 g (60%) of thedesired carboxylic acid. Electrospray Mass Spec 314.1 (M+H)⁺.

EXAMPLE 3 (trans)-2-(4-Methoxybenzenesulfonyl)aminocyclohexanecarboxylicacid t-butyl ester

To a solution of 0.313 g (1 mmol) of the product from Example 1 in 5.0mL of toluene was added 1 mL (4 mmol) of N,N-dimethylformamidedi-tert-butyl acetal. The resulting mixture was heated at 110° C. for 4h under nitrogen and then allowed to cool to room temperature. Thesolution was then poured on top of a silica gel column. Chromatographyon silica gel eluting with 10-20% ethyl acetate/hexane gave 353 mg (96%)of the desired ester as a white solid. ¹H NMR(CDCl₃): 7.8 ppm (dd, 2H,Ar), 7.0 ppm (dd, 2H, Ar), 5.7 ppm (d, 1H, NH), 3.9 ppm (s, 3H, OMe),3.4 ppm (m, 1H, N—CH), 2.5 ppm (m, 1H, CH—CO₂—), 1.0-2.0 ppm (m, 17H,hydrocarbon).

EXAMPLE 4 (cis)-2-(4-Methoxy-benzenesulfonylamino)-cyclohexanecarboxylicacid tert-butyl ester

In the same manner as described in Example 3, 1.438 g (4.59 mmol) of theproduct from Example 2 provided 0.739 g (44%) of the desired tert-butylester as a colorless oil. Electrospray Mass Spec 370.1 (M+H)⁺.

EXAMPLE 5(trans)-2-[Benzyl-(4-methoxybenzenesulfonyl)amino]-cyclohexanecarboxylicacid t-butyl ester

To a solution of 1.146 g (3.1 mmol) of the product from Example 3 in 31mL of DMF was added 0.137 g (3.42 mmol) of 60% sodium hydride. Theresulting mixture was stirred for 30 min at 25° C. and then 0.42 mL(3.50 mmol) of benzyl bromide was added all at once. This reactionmixture was stirred for 10 hr at 55° C. and then poured into water andextracted with ether. The combined organics were washed with water andbrine, dried over MgSO₄, filtered and concentrated in vacuo to provide awhite solid which was recrystallized from ethyl acetate/Hexanes toprovide 1.364 g (95%) of the desired product. ¹H NMR(CDCl₃): 7.7 ppm(dd, 2H, Ar), 7.1-7.4 (m, 5H, Ar), 6.9 ppm (dd, 2H, Ar), 4.5-4.7 ppm (ABquartet, 2H, CH₂—Ar), 3.9 ppm (s, 3H, OMe), 4.0 ppm (m, 1H, N—CH), 2.9ppm (m, 1H, CH—CO₂—), 1.0-2.3 ppm (m, 17H, hydrocarbon protons).

EXAMPLE 6(cis)-2-[Benzyl-(4-methoxy-benzenesulfonyl)-amino]-cyclohexanecarboxylicacid, tert-butyl ester

In the same manner as described in Example 5, 0.600 g (1.62 mmol) of theproduct from Example 4 provided 0.310 g (42%) of the desired benzylatedester as a colorless oil. Electrospray Mass Spec 460.1 (M+H)⁺.

EXAMPLE 7(trans)-2-[Benzyl-(4-methoxy-benzenesulfonyl)-amino]-cyclohexanecarboxylicacid

To a solution of 1.364 g (2.97 mmol) of the product from Example 5 in 10mL of dichloromethane was added 10 mL of trifluoroacetic acid and themixture was stirred for 4 h at room temperature. The solvent was thenconcentrated in vacuo and the residue was chromatographed on silica geleluting with 10-100% ethyl acetate/hexane to provide 1.092 g (73%) ofthe desired product as a white solid. Electrospray Mass Spec 404.2(M+H)⁺

EXAMPLE 8(cis)-2-[Benzyl-(4-methoxy-benzenesulfonyl)-amino]-cyclohexanecarboxylicacid

In the same manner as described in Example 7, 0.240 g (0.522 mmol) ofthe product from Example 6 provided 0.207 g (98%) of the desiredcarboxylic acid as a white solid. Electrospray Mass Spec 404.0 (M−H).

EXAMPLE 9 4-But-2-ynyloxy-benzenesulfonic acid sodium salt

To a solution of 52.35 g (0.225 mol) of 4-hydroxybenzenesulfonate sodiumsalt in 1 L of isopropanol and 225 mL of a 1.0N solution of sodiumhydroxide was added 59.96 g (0.45 mol) of 1-bromo-2-butyne. Theresulting mixture was heated to 70° for 15 h and then the isopropanolwas removed by evaporation in vacuo. The resulting white precipitate wascollected by filtration, washed with isopropanol and ether and dried invacuo to give 56.0 g (100%) of the butynyl ether as a white solid.

EXAMPLE 10 4-But-2-ynyloxy-benzenesulfonyl chloride

To a 0° solution of 43.8 mL (0.087 mol) of 2M oxalylchloride/dichloromethane solution in 29 mL of dichloromethane wasdropwise added 6.77 mL (0.087 mol) of DMF followed by 7.24 g (0.029 mol)of the product of Example 9. The reaction mixture was stirred for 10minutes at 0° then let warm to room temperature and stirred for 2 days.The reaction was then poured into ice and extracted with 150 mL ofhexanes. The organics were washed with water and brine, dried overNa₂SO₄, filtered and concentrated in vacuo to provide 6.23 g (88%) ofthe sulfonyl chloride as a yellow solid; m.p. 63-65° C. EI Mass Spec:243.9 (M⁺).

EXAMPLE 11 But-2-ynyloxy-benzene

To a solution of 6.14 g (0.023 mol) of triphenylphosphine dissolved in100 mL of benzene and 40 mL of THF was added 1.75 mL (0.023 mol) of2-butyn-1-ol. After five minutes 2.00 (0.023 mol) phenol, dissolved in10 mL of THF, was added to the reaction followed by 3.69 mL (0.023 mol)of diethyl azodicarboxylate. The resulting reaction mixture was stirredfor 18 h at room temperature and then concentrated in vacuo. The residuewas chromatographed on silica gel eluting with ethyl acetate/hexanes(1:10) to provide 2.18 g (70%) of the butynyl ether as a clear liquid.EI Mass Spec: 146.0 MH+

EXAMPLE 12 4-But-2-ynyloxy-benzenesulfonyl chloride

To a solution of 0.146 g (1.0 mmol) of the product of Example 11 in 0.3mL of dichloromethane in an acetone/ice bath under N₂ was dropwise addeda solution of 0.073 mL (1.1 mmol) of chlorosulfonic acid in 0.3 mL ofdichloromethane. After the addition was complete, the ice bath wasremoved and the reaction was stirred at room temperature for 2 h. To thereaction was then dropwise added 0.113 mL (1.3 mmol) of oxalyl chloride,followed by 0.015 mL DMF. The reaction was heated to reflux for 2 h andthen diluted with hexane and poured into ice water. The organic layerwas washed with brine, dried over sodium sulfate, and concentrated invacuo to provide 0.130 mg (53%) of the desired product as a light brownsolid.

EXAMPLE 13(1R,2R)-2-({[4-(2-Butynyloxy)phenyl]sulfonyl}amino)cyclohexanecarboxylicacid

To a room temperature solution of 1.5 g (10.2 mmol) oftrans-2-amino-1-cyclohexylcarboxylic acid in 75 ml of dioxane:H₂O (1:1)containing 2.55 ml (18.3 mmol) of triethylamine was added 3.0 g (11.2mmol) of 4-butynyloxybenzenesulfonyl chloride. The mixture was stirredat 25° C. for 18 h. The resulting mixture was diluted with ethyl acetateand washed with 1N aqueous hydrochloric acid (3×). The organic phase wasdried over anhydrous magnesium sulfate and concentrated in vacuo toafford(1R,2R)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)cyclohexanecarboxylicacid as a white solid. Electrospray Mass Spec 352.2 (M+H)⁺

EXAMPLE 14 tert-Butyl(1R,2R)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)cyclohexanecarboxylic

To a solution of 2.1 g (6 mmol) of(1R,2R)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)cyclohexanecarboxylic acid in 30 mL of toluene was added 6 mL (24 mmol)of N,N-dimethylformamide di-tert-butyl acetal. The resulting mixture washeated at 110° C. for 4 h under nitrogen and then allowed to cool toroom temperature. The solution was then poured on top of a silica gelcolumn. Chromatography on silica gel eluting with 10-20% ethylacetate/hexane gave 1.7 g oftert-butyl(1R,2R)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)cyclohexanecarboxylicas a white solid. Electrospray Mass Spec 408.3 (M+H)⁺

EXAMPLE 15 tert-Butyl(1R,2R)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]cyclohexanecarboxylic

To a solution of 1.38 g (3.4 mmol) of tert-butyl(1R,2R)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)cyclohexanecarboxylic in 20 mL of DMF was added 0.164 g (4.1 mmol) of60% sodium hydride. The resulting mixture was stirred for 30 min at 25°C. and then 0.26 mL (4.1 mmol) of iodomethane was added all at once.This reaction mixture was stirred for 0.5 hr at 25° C. and then waterand ethyl acetate were added. The organics were washed with water, driedover anhydrous potassium carbonate and concentrated in vacuo to providetert-butyl (1R,2R)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]cyclohexanecarboxylic as a white solid. Electrospray Mass Spec 422.2(M+H)⁺

EXAMPLE 16(1R,2R)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}(methyl)amino]cyclohexanecarboxylicacid

To a solution of tert-butyl(1R,2R)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]cyclohexanecarboxylicin 20 mL of dichloromethane was added 5 mL of trifluoroacetic acid andthe mixture was stirred for 3 h at room temperature. The solvent wasthen removed in vacuo and the residue was chromatographed on silica geleluting with methanol/dichloromethane. Trituration with ethylacetate/hexane provided 1.04 g of(1R,2R)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]cyclohexanecarboxylicacid as a white solid. Electrospray Mass Spec 364.3 (M−H)⁻

EXAMPLE 17(1R,2R)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}(methyl)amino]-N-hydroxycyclohexanecarboxamide

To oxalyl chloride (1.42 mL of a 2 M solution in dichloromethane) indichloromethane at 0° C. was added dimethylformamide (0.22 mL). After 15min a solution of(1R,2R)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]cyclohexanecarboxylicacid in dimethylformamide was added and the resulting reaction mixturewas stirred at room temperature for 1 h.

In a separate flask, 3 mL of triethylamine was added to a 0° C. mixtureof 0.987 g of hydroxylamine hydrochloride in 7.6 mL of THF and 3.2 mL ofwater. After this mixture had been stirred for 15 min at 0° C., the acidchloride solution was added to it in one portion and the resultingsolution was allowed to warm to room temperature and stirred for another18 h. Ethyl acetate and aqueous sodium bicarbonate were then added tothe reaction flask. The organic phase was washed with aqueous sodiumbicarbonate and dried over anhydrous potassium carbonate. Concentrationin vacuo and trituration with diethyl ether gave (1R,2R)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]-N-hydroxycyclohexanecarboxamideas a white powder (485 mg). Electrospray Mass Spec 381.2 (M+H)⁺

EXAMPLE 18(1R,2R)-2-({[4-(2-Butynyloxy)phenyl]sulfonyl}amino)-N-hydroxycyclohexanecarboxamide

In the same manner as described in Example 17, 0.50 g (1.42 mmol) of(1R,2R)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)cyclohexanecarboxylicacid provided 0.32 g of (1R,2R)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N-hydroxycyclohexanecarboxamideas a white solid. Electrospray Mass Spec 367.2 (M+H)⁺.

EXAMPLE 19 tert-Butyl3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)propanoate

To tert-butyl-2-aminopropanoate (2.0 g, 11.0 mmol) in 20 mL ofdichloromethane at 0° C. was added triethylamine (6.75 mL, 48.4 mmol)followed by 4-(2-butynyloxy)phenylsulfonyl chloride (2.94 g, 12.1 mmol).An additional 10 mL of dichloromethane was added to the thick slurry.The mixture was stirred overnight then diluted with dichloromethane andwashed sequentially with water, 2N aqueous citric acid and brine, thendried over anhydrous sodium sulfate. Filtration and concentration invacuo gave a solid that was triturated with hexanelethyl acetate to givetert-butyl 3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)propanoate (3.88g) as an off-white solid, mp 63-65° C. Analysis for C₁₇H₂₃NO₅S: Calc'd:C, 57.77; H, 6.56; N, 3.96. Found: C, 57.68; H, 6.42; N, 3.90.Electrospray Mass Spec 354.2 (M+H)⁺.

EXAMPLE 20 N-{[4-(2-Butynyloxy)phenyl]sulfonyl}-beta-alanine

In the same manner as described in Example 16 tert-butyl3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)propanoate (1.0 g, 2.83 mmol)gave N-{[4-(2-butynyloxy)phenyl]sulfonyl}-beta-alanine (1.12 g) as awhite solid. Electrospray Mass Spec 296.2 (M−H)⁻.

EXAMPLE 213-({[4-(2-Butynyloxy)phenyl]sulfonyl}amino)-N-hydroxypropanamide

To N-{[4-(2-butynyloxy)phenyl]sulfonyl}-beta-alanine (0.80 g, 2.69 mmol)in dimethylformamide (5 mL) was added 1-hydroxybenzotriazole (0.436 g,3.23 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (0.67 g,3.5 mmol). After one hour 50% hydroxylamine in water (1.3 mL) was added.The reaction mixture was stirred overnight and concentrated in vacuo.Ethyl acetate was added and the organic phase washed with water (2×) andbrine then dried over anhydrous sodium sulfate. Filtration andconcentration in vacuo gave a white solid that was triturated with ethylacetate to give3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N-hydroxypropanamide (0.30g) as a white solid,. mp 118-128° C. Electrospray Mass Spec 313.3(M+H)⁺.

EXAMPLE 22tert-Butyl-3-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]propanoate

To a solution of tert-butyl3-({[4-(2-butynyloxy)phenyl]-sulfonyl}amino)propanoate (1.0 g, 2.83mmol) in dimethylformamide (5 mL) at 0° C. was added sodium hydride(3.39 mmol) followed by iodomethane (211 uL, 3.39 mmol). After 72 hoursthe reaction mixture was diluted with ethyl acetate and washed withwater and brine and dried over anhydrous sodium sulfate. Filtration andconcentration in vacuo gavetert-butyl-3-[{[4-(2-butynyloxy)phenyl]-sulfonyl}(methyl)amino]propanoate(1.0 g) as a colorless oil. Electrospray Mass Spec 368.2 (M+H)⁺.

EXAMPLE 23 N-{[4-(2-Butynyloxy)phenyl]sulfonyl}-N-methyl-beta-alanine

In the same manner as described in Example 16tert-butyl-3-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]propanoate(0.863 g, 2.34 mmol) gaveN-{[4-(2-butynyloxy)phenyl]sulfonyl}-N-methyl-beta-alanine (0.760 g) asa white solid, mp 90-110° C. Electrospray Mass Spec 312.1 (M+H)⁺.

EXAMPLE 243-({[4-(2-Butynyloxy)phenyl]sulfonyl}(methyl)amino)-N-hydroxypropanamide

N-{[4-(2-Butynyloxy)phenyl]sulfonyl}-N-methyl-beta-alanine (0.7 g, 2.25mmol) was converted to3-({[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)-N-hydroxypropanamide(0.525 g white solid) as described in Example 21. Analysis forC₁₄H₁₈N₂O₅S: Calc'd: C, 51.52; H, 5.56; N, 8.58. Found: C, 51.38; H,5.16; N, 8.28. Electrospray Mass Spec 327.2 (M+H)⁺.

EXAMPLE 25 (1R,2S)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}aminocyclopentanecarboxylic acid

To a solution of cis-2-amino-1-cyclopentane (1.0 g, 7.74 mmol) in 1:1water:dimethylformamide (10 mL) at 0° C. was added sodium carbonate (2.7g, 25.5 mmol) followed by 4-(2-butynyloxy)phenyl sulfonyl chloride (2.08g, 8.5 mmol). The reaction mixture was allowed to warm to roomtemperature. After stirring overnight water and ethyl acetate were addedand the mixture acidified to pH=1 with 6N aqueous hydrochloric acid. Theorganic phase was washed with water and brine and dried over anhydroussodium sulfate. Filtration and concentration in vacuo gave(1R,2S)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}aminocyclopentanecarboxylic acid (1.58 g) as a white solid, mp 105-135° C.Electrospray Mass Spec 336.4 (M+H)⁺.

EXAMPLE 26(1R,2S)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}amino)-N-hydroxycyclohexanecarboxamide

(1R,2S)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}aminocyclopentanecarboxylicacid (0.506 g, 1.5 mmol) was converted to (1R,2S)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N-hydroxycyclopentanecarboxamide(0.28 g) as described in Example 21 to give an off-white solid (0.185g), mp 140-145° C. Electrospray Mass Spec 353.4 (M+H)⁺.

EXAMPLE 27 tert-Butyl (1R,2S)-²-[{[4-(2-butynyloxy)phenyl]sulfonyl}aminocyclopentanecarboxylic

(1R,2S)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}aminocyclopentanecarboxylic acid (0.80 g) was converted to tert-butyl(1R,2S)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}aminocyclopentanecarboxylate as described in Example 14 to give whitecrystals (0.60 g), mp 97-100° C. Analysis for C₂₀H₂₇NO₅: Calc'd: C,61.05; H, 6.92; N, 3.56. Found: C, 61.04; H, 6.79; N, 3.72. ElectrosprayMass Spec 394.2 (M+H)⁺.

EXAMPLE 28 tert-Butyl(1R,2S)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)aminocyclopentanecarboxylate

tert-Butyl(1R,2S)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}aminocyclopentanecarboxylate(0.50 g, 1.27 mmol) in dimethylformamide (4 mL) was treated withpotassium carbonate (0.527 g, 3.81 mmol) and iodomethane (95 uL, 1.53mmol). After 18 hours the reaction mixture was concentrated in vacuo,diluted with ethyl acetate and washed with water and brine then driedover anhydrous sodium sulfate. Filtration and concentration in vacuogave tert-butyl(1R,2S)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)aminocyclopentanecarboxylate as a white solid (0.495 g), mp 131-133° C.Electrospray Mass Spec 408.2 (M+H)⁺.

EXAMPLE 29(1R,2S)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}(methyl)amino]cyclopentanecarboxylicacid

tert-Butyl (1R,2S)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}aminocyclopentanecarboxylate (0.44 g) was converted to(1R,2S)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]cyclopentanecarboxylicacid as described in Example 16 to give a white solid (0.375 g).Electrospray Mass Spec 352.2 (M+H)⁺.

EXAMPLE 30(1R,2S)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}(methyl)amino]N-hydroxycyclopentanecarboxamide

(1R,2S)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}(methyl)amino]cyclopentanecarboxylicacid (0.320 g) was converted to(1R,2S)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]N-hydroxycyclopentanecarboxamideas described in Example 21 to give white crystals (0.105 g), mp 160-164°C. Analysis for C₁₇H₂₂N₂O₅S: Calc'd: C, 55.72; H, 6.05; N, 7.64. Found:C, 55.40; H, 6.15; N, 7.50. Electrospray Mass Spec 367.25 (M+H)⁺.

EXAMPLE 31 (Cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}aminocyclohexanecarboxylic acid

Cis-2-amino-1-cyclohexane (1.2 g, 8.38 mmol) was converted to(cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}amino cyclohexanecarboxylicacid as described in Example 25 to give a white solid (0.825 g), mp172-175° C. Analysis for C₁₇H₂₁NO₅S: Calc'd: C, 58.10; H, 6.02; N, 3.99.Found: C, 58.32; H, 5.92; N, 3.87. Electrospray Mass Spec 350.1 (M−H)⁻.

EXAMPLE 32(Cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N-hydroxycyclohexanecarboxamide

(Cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}amino cyclohexanecarboxylicacid (0.300 g, 0.854 mmol) was converted to(cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N-hydroxycyclohexanecarboxamideas described in Example 21 to give an off-white foam (0.210 g).Electrospray Mass Spec 367.2 (M+H)⁺.

EXAMPLE 33(Cis)-tert-butyl-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}amino)cyclohexanecarboxylic

(Cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}amino cyclohexanecarboxylicacid (0.38 g, 1.08 mmol) was converted to(cis)-tert-butyl-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}amino)cyclohexanecarboxylicas described in Example 14 to give a white solid (0.450 g). ElectrosprayMass Spec 408.2 (M+H)⁺.

EXAMPLE 34(Cis)-tert-butyl-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)cyclohexanecarboxylic

(Cis)-tert-butyl-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}amino)cyclohexanecarboxylic(0.390 g, 0.956 mmol) was converted to(cis)-tert-butyl-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)cyclohexanecarboxylicas described in Example 28 to give a colorless oil (0.260 g).Electrospray Mass Spec 422.2 (M+H)⁺.

EXAMPLE 35(Cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)cyclohexanecarboxylicacid

(Cis)-tert-butyl-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)cyclohexanecarboxylic(0.220 g, 0.522 mmol) was converted to(cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)cyclohexanecarboxylicacid as described in Example 16 to give a white solid (0.190 g).Electrospray Mass Spec 366.2 (M+H)⁺.

EXAMPLE 36(Cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]-N-hydroxycyclohexanecarboxamide

(Cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)cyclohexanecarboxylicacid (0.165 g, 0.45 mmol) was converted to(cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]-N-hydroxycyclohexanecarboxamideas described in Example 21 to give an off white solid (0.50 g).Electrospray Mass Spec 381.2 (M+H)⁺.

EXAMPLE 37(1R,2R,3S,4R)-(Cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)bicyclo[2.2.1]heptane-2-carboxylicacid

3-Exo-aminobicyclo[2.2.1]heptane-2-exo carboxylic acid (1.0 g, 6.44mmol) was converted to(1R,2R,3S,4R)-(cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)bicyclo[2.2.1]heptane-2-carboxylicacid as described in Example 25 to give a white solid (1.32 g), mp195-215° C. Electrospray Mass Spec 364.3 (M+H)⁺.

EXAMPLE 38(1R,2R,3S,4R)-(Cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N-hydroxybicyclo[2.2.1]heptane-2-carboxamide

(1R,2R,3S,4R)-(Cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)bicyclo[2.2.1]heptane-2-carboxylicacid (0.363 g, 1 mmol) was converted to(1R,2R,3S,4R)-(cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N-hydroxybicyclo[2.2.1]heptane-2-carboxamideas described in Example 21 to give a white solid (0.30 g). Analysis forC₁₈H₂₂N₂O₅S: Calc'd: C, 57.13; H, 5.86; N, 7.4. Found: C, 57.76; H,6.12; N, 7.6. Electrospray Mass Spec 379.3 (M+H)⁺.

EXAMPLE 39 tert-Butyl(1R,2R,3S,4R)-(cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)bicyclo[2.2.1]heptane-2-carboxylate

(1R,2R,3S,4R)-(Cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)bicyclo[2.2.1]heptane-2-carboxylicacid (0.80 g, 2.2 mmol) was converted to tert-butyl(1R,2R,3S,4R)-(cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)bicyclo[2.2.1]heptane-2-carboxylateas described in Example 14 to give a white solid (0.69 g), mp 94-99° C.Analysis for C₂₂H₂₉NO₅S: Calc'd: C, 62.98; H, 6.97; N, 3.34. Found: C,62.65; H, 6.95; N, 3.7. Electrospray Mass Spec 420.3 (M+H)⁺.

EXAMPLE 40 tert-Butyl(1R,2R,3S,4R)-(cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)bicyclo[2.2.1]heptane-2-carboxylate

tert-Butyl(1R,2R,3S,4R)-(cis)-3-({[4-(2-butynyloxy)phenyl]-sulfonyl}amino)bicyclo[2.2.1]heptane-2-carboxylate(0.55g, 1.31 mmol) was converted to tert-butyl(1R,2R,3S,4R)-(cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)bicyclo[2.2.1]heptane-2-carboxylateas described in Example 28 to give a white solid (0.54 g), mp 120-125°C. Analysis for C₂₃H₃₁NO₅S: Calcd: C, 63.72; H, 7.21; N, 3.23. Found: C,63.34; H, 7.11; N, 3.55. Electrospray Mass Spec 434.2 (M+H)⁺.

EXAMPLE 41(1R,2R,3S,4R)-(Cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)bicyclo[2.2.1]heptane-2-carboxylicacid

tert-Butyl(1R,2R,3S,4R)-(cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)bicyclo[2.2.1]heptane-2-carboxylate(0.45 g, 1.04 mmol) was converted to(1R,2R,3S,4R)-(cis)-3-({[4-(2-butynyloxy)phenyl]isulfonyl}(methyl)amino)bicyclo[2.2.1]heptane-2-carboxylicacid as described in Example 16 to give a white solid (0.37 g), mp153-158° C. Analysis for C₁₉H₂₃NO₅S: Calc'd: C, 60.46; H, 6.14; N, 3.71.Found: C, 60.71; H, 5.94; N, 3.97. Electrospray Mass Spec 378.1 (M+H)⁺.

EXAMPLE 42(1R,2R,3S,4R)-(Cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)-N-hydroxybicyclo[2.2.1]heptane-2-carboxamide

(1R,2R,3S,4R)-(Cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)bicyclo[2.2.1]heptane-2-carboxylicacid (0.30 g, 0.79 mmol) was converted to(1R,2R,3S,4R)-(cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)-N-hydroxybicyclo[2.2.1]heptane-2-carboxamide(0.137 g) as described in Example 21. Electrospray Mass Spec 393.2(M+H)⁺.

Pharmacology

The ability of the compounds of the invention, or their pharmaceuticallyacceptable salts, to inhibit matrix metalloproteinases or TACE and,consequently, demonstrate their effectiveness for treating diseasesmodulated by matrix metalloproteinases or TACE is shown by the followingin vitro assays.

Test Procedures for Measuring MMP-1, MMP-9, and MMP-13 Inhibition

These standard pharmacological test procedures are based on the cleavageof a thiopeptide substrates such asAc-Pro-Leu-Gly(2-mercapto-4-methyl-pentanoyl)-Leu-Gly-OEt by the matrixmetalloproteinases MMP-1, MMP-13 (collagenases) or MMP-9 (gelatinase),which results in the release of a substrate product that reactscalorimetrically with DTNB (5,5′-dithiobis(2-nitro-benzoic acid)). Theenzyme activity is measured by the rate of the color increase. Thethiopeptide substrate is made up fresh as a 20 mM stock in 100% DMSO andthe DTNB is dissolved in 100% DMSO as a 100 mM stock and stored in thedark at room temperature. Both the substrate and DTNB are dilutedtogether to 1 mM with substrate buffer (50 mM HEPES pH 7.5, 5 mM CaCl₂)before use. The stock of enzyme is diluted with buffer (50 mM HEPES, pH7.5, 5 mM CaCl₂, 0.02% Brij) to the desired final concentration. Thebuffer, enzyme, vehicle or inhibitor, and DTNB/substrate are added inthis order to a 96 well plate (total reaction volume of 200 μl) and theincrease in color is monitored spectrophotometrically for 5 minutes at405 nm on a plate reader and the increase in color over time is plottedas a linear line.

Alternatively, a fluorescent peptide substrate is used. In this testprocedure, the peptide substrate contains a fluorescent group and aquenching group. Upon cleavage of the substrate by an MMP, thefluorescence that is generated is quantitated on the fluorescence platereader. The assay is run in HCBC assay buffer (50 mM HEPES, pH 7.0, 5 mMCa⁺², 0.02% Brij, 0.5% Cysteine), with human recombinant MMP-1, MMP-9,or MMP-13. The substrate is dissolved in methanol and stored frozen in 1mM aliquots. For the assay, substrate and enzymes are diluted in HCBCbuffer to the desired concentrations. Compounds are added to the 96 wellplate containing enzyme and the reaction is started by the addition ofsubstrate. The reaction is read (excitation 340 nm, emission 444 nm) for10 min. and the increase in fluorescence over time is plotted as alinear line.

For either the thiopeptide or fluorescent peptide test procedures, theslope of the line is calculated and represents the reaction rate. Thelinearity of the reaction rate is confirmed (r²>0.85). The mean (x±sem)of the control rate is calculated and compared for statisticalsignificance (p<0.05) with drug-treated rates using Dunnett's multiplecomparison test. Dose-response relationships can be generated usingmultiple doses of drug and IC₅₀ values with 95% CI are estimated usinglinear regression.

Test Procedure for Measuring TACE Inhibition

Using 96-well black microtiter plates, each well receives a solutioncomposed of 10 μL TACE (fmal concentration 1 μg/mL), 70 μL Tris buffer,pH 7.4 containing 10% glycerol (final concentration 10 mM), and 10 μL oftest compound solution in DMSO (final concentration 1 μM, DMSOconcentration <1%) and incubated for 10 minutes at room temperature. Thereaction is initiated by addition of a fluorescent peptidyl substrate(final concentration 100 μM) to each well and then shaking on a shakerfor 5 sec.

The reaction is read (excitation 340 nm, emission 420 nm) for 10 min.and the increase in fluorescence over time is plotted as a linear line.The slope of the line is calculated and represents the reaction rate.

The linearity of the reaction rate is confirmed (r²>0.85). The mean(x±sem) of the control rate is calculated and compared for statisticalsignificance (p<0.05) with drug-treated rates using Dunnett's multiplecomparison test. Dose-response relationships can be generate usingmultiple doses of drug and IC₅₀ values with 95% CI are estimated usinglinear regression.

Human Monocytic THP-1 Cell Differentiation Assay for Soluble Proteins(THP-1 Soluble Protein Assay)

Mitogenic stimulation of THP-1 cells cause differentiation intomacrophage like cells with concomitant secretion of tumor necrosisfactor (TNF-α and TNF receptor (TNF-R p75/80 and TNF-R p55/60) andInterleukin-8 (IL-8), among other proteins. In addition, non-stimulatedTHP-1 cells shed both the p75/80 and the p55/60 receptors over time. Therelease of membrane bound TNF-α and possibly TNF-R p75/80 and TNF-Rp55/60, but not IL-8, is mediated by an enzyme called TNF-α convertingenzyme or TACE. This assay can be used to demonstrate either aninhibitory or a stimulatory compound effect on this TACE enzyme and anycytotoxic consequence of such a compound.

THP-1 cells (from ATCC) are a human monocytic cell line which wereobtained from the peripheral blood of a one year old male with acutemonocytic leukemia. They can be grown in culture and differentiated intomacrophage like cells by stimulation with mitogens.

For the assay, THP-1 cells are seeded from an ATCC stock which waspreviously grown and frozen back at 5×106/ml/vial. One vial is seededinto a T25-flask with 16 mls of RPMI-1640 with glutamax (Gibco) mediacontaining 10% fetal bovine serum, 100 units/ml penicillin, 100 μg/mlstreptomycin, and 5×10⁻⁵ M 2-mercapto-ethanol (THP-1 media). Each vialof cells are cultured for about two weeks prior to being used for anassay and then are used for only 4 to 6 weeks to screen compounds. Cellsare subcultured on Mondays and Thursdays to a concentration of 1×105/ml.

To perform an assay, the THP-1 cells are co-incubated in a 24 well platewith 50 ml/well of a 24 mg/ml stock of Lipopolysacharide (LPS)(Calbiochem Lot# B13189) at 37° C. in 5% CO₂ at a concentration of1.091×10⁶ cells/ml (1.1 ml/well) for a total of 24 hours. At the sametime, 50 ml/well of drug, vehicle or THP-1 media is plated inappropriate wells to give a final volume of 1.2 ml/well. Standard andtest compounds are dissolved in DMSO at a concentration of 36 mM anddiluted from here to the appropriate concentrations in THP-1 media andadded to the wells at the beginning of the incubation period to givefinal concentrations of 100 mM, 30 mM, 10 mM, 3 mM, 1 mM, 300 nM, and100 nM. Cell exposure to DMSO was limited to 0.1% final concentration.Positive control wells were included in the experiment which had mitogenadded but no drug. Vehicle control wells were included as well, whichwere identical to the positive control wells, except that DMSO was addedto give a final concentration of 0.083%. Negative control wells wereincluded in the experiment which had vehicle but no mitogen or drugadded to the cells. Compounds can be evaluated for their effect on basal(non-stimulated) shedding of the receptors by replacing the LPS with 50ml/well of THP-1 media. Plates are placed into an incubator set at 5%CO2 and at 37° C. After 4 hours of incubation, 300 ml/well of tissueculture supernatant (TCS) is removed for use in an TNF-α ELISA.Following 24 hours of incubation, 700 ml/well of TCS is removed and usedfor analysis in TNF-R p75/80, TNF-R p55/60 and IL-8 ELISAs.

In addition, at the 24 hours timepoint, and the cells for each treatmentgroup are collected by resuspension in 500 μl/well of THP-1 media andtransferred into a FACS tube. Two ml/tube of a 0.5 mg/ml stock ofpropidium iodide (PI) (Boerhinger Mannheim cat. # 1348639) is added. Thesamples are run on a Becton Dickinson FaxCaliber FLOW cytometry machineand the amount of dye taken up by each cell is measured in the high redwavelength (FL3). Only cells with compromised membranes (dead or dying)can take up PI. The percent of live cells is calculated by the number ofcells not stained with PI, divided by the total number of cells in thesample. The viability values calculated for the drug treated groups werecompared to the viability value calculated for the vehicle treatedmitogen stimulated group (“vehicle positive control”) to determine the“percent change from control”. This “percent change from control” valueis an indicator of drug toxicity.

The quantity of soluble TNF-α, TNF-R p75/80 and TNF-R p55/60 and IL-8 inthe TCS of the THP-1 cell cultures are obtained with commerciallyavailable ELISAs from R&D Systems, by extrapolation from a standardcurve generated with kit standards. The number of cells that either takeup or exclude PI are measured by the FLOW cytometry machine andvisualized by histograms using commercially available Cytologic softwarefor each treatment group including all controls.

Biological variability in the magnitude of the response of THP-1 cellcultures requires that experiments be compared on the basis of percentchange from “vehicle positive control” for each drug concentration.Percent change in each soluble protein evaluated from the “vehiclepositive control” was calculated for each compound concentration withthe following formula:$\text{\% Change} = {\frac{\text{pg/ml (compound)} - \text{pg/ml (veh pos control)}}{\text{pg/ml (veh pos control)} - \text{pg/ml (veh neg control)}} \times 100}$

For the soluble protein (TNF-α, p75/80, p55/60, IL-8) studies understimulated conditions, the mean pg/ml of duplicate wells were determinedand the results expressed as percent change from “vehicle positivecontrol”. For the soluble protein (p75/80 and p55/60 receptors) studiesunder non-stimulated conditions, the mean pg/ml of duplicate wells weredetermined and the results expressed as percent change from “vehiclepositive control” utilizing the following formula: $\begin{matrix}{\text{\% Change} = {\frac{\text{pg/ml (compound neg control)} - \text{pg/ml (veh neg control}}{\text{pg/ml (veh neg control)}} \times 100}} & \quad\end{matrix}$

IC50 values for each compound are calculated by non-linear regressionanalysis using customized software utilizing the JUMP statisticalpackage.

For the cell viability studies, the viabilities (PI exclusion) of pooledduplicate wells were determined and the results expressed as % changefrom “vehicle positive control”. The viability values calculated for thecompound treated groups were compared to the viability value calculatedfor the “vehicle positive control” to determine “percent change fromcontrol” as below. This value “percent change from control ” is anindicator of drug toxicity.$\text{\% Change} = {\frac{\text{\% live cells (compound)}}{\text{\% live cells (veh pos control)}} - {1 \times 100}}$

REFERENCES

Bjornberg, F., Lantz, M., Olsson, I., and Gullberg, U. Mechanismsinvolved in the processing of the p55 and the p75 tumor necrosis factor(TNF) receptors to soluble receptor forms. Lymphokine Cytokine Res.13:203-211, 1994.

Gatanaga, T., Hwang, C., Gatanaga, M., Cappuccini, F., Yamamoto, R., andGranger, G. The regulation of TNF mRNA synthesis, membrane expression,and release by PMA- and LPS-stimulated human monocytic THP-1 cells invitro. Cellular Immun. 138:1-10, 1991.

Tsuchiya, S., Yamabe, M., Yamagughi, Y., Kobayashi, Y., Konno, T., andTada, K. Establishment and characterization of a human acute monocyticleukemia cell line (THP-1). Int. J. Cancer. 26:1711-176, 1980.

Results of the above in vitro matrix metalloproteinase inhibition, TACEinhibition, and THP standard pharmacological test procedures are givenin Table 1.

TABLE 1 Example # MMP-1^(a) MMP-9^(a) MMP-13^(a) TACE^(a) THP^(b) 17 >10uM >10 uM >10 uM 28 14 18 >10 uM >10 uM >10 uM 61 1 21 >10 uM >10 uM >10uM 145 0 24 >10 uM ˜10 uM ˜10 uM 73 9 26 >1 uM 5056 672 15 23 30 2768383 308 14 65 32 >10 uM ˜10 uM 1738 36 29 36 4229 1319 1820 53 23 38 >10uM >10 uM ˜10 uM 30 9 42 ˜10 uM — 1142 62 77 ^(a)IC₅₀ (nM) ^(b)%Inhibition @ 3 μM

Based on the standard pharmacological test procedures described above,the compounds of this invention are useful in the treatment of disorderssuch as arthritis, tumor metastasis, tissue ulceration, abnormal woundhealing, periodontal disease, graft rejection, insulin resistance, bonedisease and HIV infection.

The compounds of this invention are also useful in treating orinhibiting pathological changes mediated by matrix metalloproteinasessuch as atherosclerosis, atherosclerotic plaque formation, reduction ofcoronary thrombosis from atherosclerotic plaque rupture, restenosis,MMP-mediated osteopenias, inflammatory diseases of the central nervoussystem, skin aging, angiogenesis, tumor metastasis, tumor growth,osteoarthritis, rheumatoid arthritis, septic arthritis, cornealulceration, proteinuria, aneurysmal aortic disease, degenerativecartilage loss following traumatic joint injury, demyelinating diseasesof the nervous system, cirrhosis of the liver, glomerular disease of thekidney, premature rupture of fetal membranes, infammatory bowel disease,age related macular degeneration, diabetic retinopathy, proliferativevitreoretinopathy, retinopathy of prematurity, ocular inflammation,keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocularangiogenesis/neovascularization and corneal graft rejection.

Compounds of this invention may be administered neat or with apharmaceutical carrier to a patient in need thereof. The pharmaceuticalcarrier may be solid or liquid.

Applicable solid carriers can include one or more substances which mayalso act as flavoring agents, lubricants, solubilizers, suspendingagents, fillers, glidants, compression aids, binders ortablet-disintegrating agents or an encapsulating material. In powders,the carrier is a finely divided solid which is in admixture with thefinely divided active ingredient. In tablets, the active ingredient ismixed with a carrier having the necessary compression properties insuitable proportions and compacted in the shape and size desired. Thepowders and tablets preferably contain up to 99% of the activeingredient. Suitable solid carriers include, for example, calciumphosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch,gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose,polyvinylpyrrolidine, low melting waxes and ion exchange resins.

Liquid carriers may be used in preparing solutions, suspensions,emulsions, syrups and elixirs. The active ingredient of this inventioncan be dissolved or suspended in a pharmaceutically acceptable liquidcarrier such as water, an organic solvent, a mixture of both orpharmaceutically acceptable oils or fat. The liquid carrier can containother suitable pharmaceutical additives such a solubilizers,emulsifiers, buffers, preservatives, sweeteners, flavoring agents,suspending agents, thickening agents, colors, viscosity regulators,stabilizers or osmo-regulators. Suitable examples of liquid carriers fororal and parenteral administration include water (particularlycontaining additives as above, e.g., cellulose derivatives, preferablesodium carboxymethyl cellulose solution), alcohols (including monohydricalcohols and polyhydric alcohols, e.g., glycols) and their derivatives,and oils (e.g., fractionated coconut oil and arachis oil). Forparenteral administration the carrier can also be an oily ester such asethyl oleate and isopropyl myristate. Sterile liquid carriers are usedin sterile liquid form compositions for parenteral administration.

Liquid pharmaceutical compositions which are sterile solutions orsuspensions can be utilized by, for example, intramuscular,intraperitoneal or subcutaneous injection. Sterile solutions can also beadministered intravenously. Oral administration may be either liquid orsolid composition form.

The compounds of this invention may be administered rectally in the formof a conventional suppository. For administration by intranasal orintrabronchial inhalation or insufflation, the compounds of thisinvention may be formulated into an aqueous or partially aqueoussolution, which can then be utilized in the form of an aerosol. Thecompounds of this invention may also be administered transdermallythrough the use of a transdermal patch containing the active compoundand a carrier that is inert to the active compound, is non-toxic to theskin, and allows delivery of the agent for systemic absorption into theblood stream via the skin. The carrier may take any number of forms suchas creams and ointments, pastes, gels, and occlusive devices. The creamsand ointments may be viscous liquid or semi-solid emulsions of eitherthe oil in water or water in oil type. Pastes comprised of absorptivepowders dispersed in petroleum or hydrophilic petroleum containing theactive ingredient may also be suitable. A variety of occlusive devicesmay be used to release the active ingredient into the blood stream suchas a semipermeable membrane covering a reservoir containing the activeingredient with or without a carrier, or a matrix containing the activeingredient. Other occlusive devices are known in the literature.

The dosage to be used in the treatment of a specific patient suffering aMMP or TACE dependent condition must be subjectively determined by theattending physician. The variables involved include the severity of thedysfunction, and the size, age, and response pattern of the patient.Treatment will generally be initiated with small dosages less than theoptimum dose of the compound. Thereafter the dosage is increased untilthe optimum effect under the circumstances is reached. Precise dosagesfor oral, parenteral, nasal, or intrabronchial administration will bedetermined by the administering physician based on experience with theindividual subject treated and standard medical principles.

Preferably the pharmaceutical composition is in unit dosage form, e.g.,as tablets or capsules. In such form, the composition is sub-divided inunit dose containing appropriate quantities of the active ingredient;the unit dosage form can be packaged compositions, for example packedpowders, vials, ampoules, prefilled syringes or sachets containingliquids. The unit dosage form can be, for example, a capsule or tabletitself, or it can be the appropriate number of any such compositions inpackage form.

What is claimed:
 1. Hydroxamide acids of the formula:

where the C(═O)NHOH moiety and the —NR5- moiety are bonded to adjacentcarbons; wherein X is SO₂ or —P(O)R₁₀; Y is 5-10 membered heteroarylring having from 1-3 heteroatoms selected from N, NR9, S and O, phenylor naphthyl; with the proviso that X and Z may not be bonded to adjacentatoms of Y: Z is O, NH, CH₂ or S; R₅ is hydrogen or alkyl of 1-6 carbonatoms; R₆and R₇ are each, independently, hydrogen or methyl; R₈ ishydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms,alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, a 5-7membered heteroaryl having 1-3 heteroatoms selected from N, NR9, S andO, a 5-7 membered heterocycloalkyl having 1 or 2 heteroatoms selectedfrom N, NR9, S and O, or phenyl; R₉ is hydrogen, alkyl of 1-6 carbonatoms, cycloalkyl of 3-6 carbon atoms, or phenyl; R₁₀ is alkyl of 1-6carbon atoms, cycloalkyl of 3-6 carbon atoms, phenyl, or 5-7 memberedheteroaryl, having 1-3 heteroatoms selected from N, NR9, S and O; R11and R12 are, independently, hydrogen, alkyl of 1-6 carbon atoms,cycloalkyl of 3-6 carbon atoms, a 5-7 membered heteroaryl having 1-3heteroatoms selected from N, NR9, S and O, a 5-7 memberedheterocycloalkyl having 1 or 2 heteroatoms selected from N, NR9, S andO, or phenyl, and the optional double bond represented by the dottedline is present; or R11 and R12, together with the carbons to which theyare attached, form a 5-10 membered saturated or unsaturated mono orbicyclic cycloalkyl optionally fused to one of a 5 to 7 memberedsaturated or unsaturated cycloalkyl ring, a 5-7 membered heteroarylhaving 1-3 heteroatoms selected from N, NR9, S and O, a 5-7 memberedheterocycloalkyl having 1 or 2 heteroatoms selected from N, NR9, S andO, phenyl or napthyl rings; or R11 and R12, together with the carbons towhich they are attached form a 5-10 membered saturated or unsaturatedmono- or bicyclic heterocycloalkyl having 1-2 heteroatoms selected fromN, NR9, S and O, optionally fused to one of a 5-7 membered mono orbi-cyclic heteroaryl having 1-3 heteroatoms selected from N, NR9, S andO, a 5-7 membered saturated or unsaturated cycloalkyl ring or a phenylor napthyl ring; the dotted line represents an optional double bond; andn=0-2; or a pharmaceutically acceptable salt thereof.
 2. A compoundaccording to claim 1 wherein X is SO₂.
 3. A compound according to claim1 wherein X is SO₂ and Y is a phenyl ring substituted at the 1- and4-positions by X and Z, respectively.
 4. A compound according to claim 1wherein X is SO₂, Y is a phenyl ring substituted at the 1- and4-positions by X and Z, respectively, and Z is oxygen.
 5. A compoundaccording to claim 1 wherein X is SO₂, Y is a phenyl ring substituted atthe 1- and 4-positions by X and Z, respectively, Z is oxygen and R₆ andR₇ are hydrogen.
 6. A compound according to claim 1 wherein X is SO₂, Yis a phenyl ring substituted at the 1- and 4-positions by X and Z,respectively, Z is oxygen, R₆ and R₇ are hydrogen, and R₈ is —CH₂OH ormethyl.
 7. A compound according to claim 1 which is selected from thegroup consisting of(1R,2R)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}(methyl)amino]-N-hydroxycyclohexanecarboxamide;(1R,2R)-2-({[4-(2-Butynyloxy)phenyl]sulfonyl}amino)-N-hydroxycyclohexanecarboxamide;3-({[4-(2-Butynyloxy)phenyl]sulfonyl}amino)-N-hydroxypropanamide;3-({[4-(2-Butynyloxy)phenyl]sulfonyl}(methyl)amino)-N-hydroxypropanamide;(1R,2S)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}amino)-N-hydroxycyclopentanecarboxamide;(1R,2S)-2-[{[4-(2-Butynyloxy)phenyl]sulfonyl}(methyl)amino]N-hydroxycyclopentanecarboxamide;(Cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N-hydroxycyclohexanecarboxamide;(Cis)-2-[{[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino]-N-hydroxycyclohexanecarboxamide;(1R,2R,3S,4R)-(Cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N-hydroxybicyclo[2.2.1]heptane-2-carboxamide;and(1R,2R,3S,4R)-(Cis)-3-({[4-(2-butynyloxy)phenyl]sulfonyl}(methyl)amino)-N-hydroxybicyclo[2.2.1]heptane-2-carboxamide.8. A compound of the formula,

wherein R₆ and R₇ are each, independently, hydrogen, alkyl of 1-6 carbonatoms, —CN, —CCH; and R₈ is alkyl of 1-6 carbon atoms, alkenyl of 2-6carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbonatoms, phenyl, naphthyl, 5 to 10 membered heteroaryl having from 1 to 3heteoatoms selected from N, NR9, O or S, or 5 to 9 memberedheterocycloalkyl having 1 or 2 heteroatoms selected from N, NR9, O or S.9. A compound of the formula

wherein R₆ and R₇ are each, independently, hydrogen, alkyl of 1-6 carbonatoms, —CN, —CCH; R₈ is of 1-6 carbon atoms, alkenyl of 2-6 carbonatoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms,phenyl, naphthyl, 5 to 10 membered heteroaryl having from 1 to 3heteoatoms selected from N, NR9, O or S, or 5 to 9 memberedheterocycloalkyl having 1 or 2 heteroatoms selected from N, NR9, O or S;and J is fluorine, bromine, chlorine, 1,2,4-triazolyl, benzotriazolyl orimidazol-yl.
 10. A method of inhibiting pathological changes mediated byTNF-α converting enzyme (TACE) in a mammal in need thereof whichcomprises administering to said mammal a therapeutically effectiveamount of a compound having the formula:

where the C(═O)NHOH moiety and the —NR5— moiety are bonded to adjacentcarbons; wherein X is SO₂ or —P(O)R₁₀; Y is 5-10 membered heteroarylring having from 1-3 heteroatoms selected from N, NR9, S and O, phenylor naphthyl; with the proviso that X and Z may not be bonded to adjacentatoms of Y: Z is O, NH, CH₂ or S; R₅ is hydrogen or alkyl of 1-6 carbonatoms; R₆ and R₇ are each, independently, hydrogen or methyl; R₈ ishydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms,alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, a 5-7membered heteroaryl having 1-3 heteroatoms selected from N, NR9, S andO, a 5-7 membered heterocycloalkyl having 1 or 2 heteroatoms selectedfrom N, NR9, S and O, or phenyl; R₉ is hydrogen, alkyl of 1-6 carbonatoms, cycloalkyl of 3-6 carbon atoms, or phenyl; R₁₀ is alkyl of 1-6carbon atoms, cycloalkyl of 3-6 carbon atoms, phenyl, or L; R11and R12are, independently, hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl of3-6 carbon atoms, a 5-7 membered heteroaryl having 1-3 heteroatomsselected from N, NR9, S and O, a 5-7 membered heterocycloalkyl having 1or 2 heteroatoms selected from N, NR9, S and O, or phenyl, and theoptional double bond represented by the dotted line is present; or R11and R12, together with the carbons to which they are attached, form a5-10 membered saturated or unsaturated mono or bicyclic cycloalkyloptionally fused to a 5 to 7 membered saturated or unsaturatedcycloalkyl ring, a 5-7 membered heteroaryl having 1-3 heteroatomsselected from N, NR9, S and O, a 5-7 membered heterocycloalkyl having 1or 2 heteroatoms selected from N, NR9, S and O, phenyl or napthyl rings;or R11 and R12, together with the carbons to which they are attachedform a 5-10 membered saturated or unsaturated mono- or bicyclicheterocycloalkyl having 1-2 heteroatoms selected from N, NR9, S and O,optionally fused to a 5-7 membered mono or bi-cyclic heteroaryl having1-3 heteroatoms selected from N, NR9, S and O, a 5-7 membered saturatedor unsaturated cycloalkyl ring or a phenyl or napthyl ring; the dottedline represents an optional double bond; L is heteroaryl; and n=0-2; ora pharmaceutically acceptable salt thereof.
 11. The method according toclaim 9 wherein the condition treated is rheumatoid arthritis, graftrejection, cachexia, inflammation, fever, insulin resistance, septicshock, congestive heart failure, inflammatory disease of the centralnervous system, inflammatory bowel disease or HIV infection.
 12. Apharmaceutical composition comprising a compound having the formulaformula:

where the C(═O)NHOH moiety and the —NR5— moiety are bonded to adjacentcarbons; wherein X is SO₂ or —P(O)R₁₀; Y is 5-10 membered heteroarylring having from 1-3 heteroatoms selected from N, NR9, S and O, phenylor naphthyl; with the proviso that X and Z may not be bonded to adjacentatoms of Y: Z is O, NH, CH₂ or S; R₅ is hydrogen or alkyl of 1-6 carbonatoms; R₆ and R₇ are each, independently, hydrogen or methyl; R₈ ishydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms,alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, a 5-7membered heteroaryl having 1-3 heteroatoms selected from N, NR9, S andO, a 5-7 membered heterocycloalkyl having 1 or 2 heteroatoms selectedfrom N, NR9, S and O, or phenyl; R₉ is hydrogen, alkyl of 1-6 carbonatoms, cycloalkyl of 3-6 carbon atoms, or phenyl; R₁₀ is alkyl of 1-6carbon atoms, cycloalkyl of 3-6 carbon atoms, phenyl, or L; R11 and R12are, independently, hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl of3-6 carbon atoms, a 5-7 membered heteroaryl having 1-3 heteroatomsselected from N, NR9, S and O, a 5-7 membered heterocycloalkyl having 1or 2 heteroatoms selected from N, NR9, S and O, or phenyl, and theoptional double bond represented by the dotted line, is present; or R11and R12, together with the carbons to which they are attached, form a5-10 membered saturated or unsaturated mono or bicyclic cycloalkyloptionally fused to a 5 to 7 membered saturated or unsaturatedcycloalkyl ring, a 5-7 membered heteroaryl having 1-3 heteroatomsselected from N, NR9, S and O, a 5-7 membered heterocycloalkyl having 1or 2 heteroatoms selected from N, NR9, S and O, phenyl or napthyl rings;or R11 and R12, together with the carbons to which they are attachedform a 5-10 membered saturated or unsaturated mono- or bicyclicheterocycloalkyl having 1-2 heteroatoms selected from N, NR9, S and O,optionally fused to a 5-7 membered mono or bi-cyclic heteroaryl having1-3 heteroatoms selected from N, NR9, S and O, a 5-7 membered saturatedor unsaturated cycloalkyl ring or a phenyl or napthyl ring; the dottedline represents an optional double bond; L is heteroaryl; and n=0-2; ora pharmaceutically acceptable salt thereof; and a pharmaceuticallyacceptable carrier.